Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Bionow BioIgnite

Launching in 2025, the Bionow BioIgnite event series is a fresh addition inspired by the successful BioFocus format. Designed to connect industry and academia, BioIgnite [...]

Go to Top